Open Access
Numéro |
Cah. Myol.
Numéro 15, Juin 2017
|
|
---|---|---|
Page(s) | 30 - 33 | |
Section | Prise en charge / Management | |
DOI | https://doi.org/10.1051/myolog/201715007 | |
Publié en ligne | 23 juin 2017 |
- Dubowitz V. 75th European neuromuscular centre international workshop on the treatment of muscular dystrophy, 10-12 December 1999, Naarden, The Netherlands. Neuromuscul Disord 2000; 10 : 313–20. [PubMed] [Google Scholar]
- Zatz M, Pavanello Rde C, Vainzof M, et al. Steroids in Duchenne muscular dystrophy. Neuromuscul Disord 1992; 2 : 59 [PubMed] [Google Scholar]
- Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2016; 5 : CD003725. [Google Scholar]
- McAdam LC, Mayo AL, Alman BA, Biggar WD. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. Acta Myol 2012; 31 : 16–20. [PubMed] [Google Scholar]
- Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatr 2013;84: 698–705. [Google Scholar]
- Buyse GM, Goemans N, van den Hauwe M, et al. Effects of glucocorticoids and idebenone on respiratory function in patients with Duchenne muscular dystrophy. Pediatr Pulmonol 2013; 48 : 912–20. [CrossRef] [PubMed] [Google Scholar]
- Barber BJ, Andrews JG, Lu Z, et al. Oral corticosteroids at onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr 2013; 163 : 1080–4e1. [CrossRef] [PubMed] [Google Scholar]
- Lebel DE, Corston JA, McAdam LC, et al. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long term follow up. J Bone Joint Surg Am 2013;95: 1057–61. [PubMed] [Google Scholar]
- Schram G, Fournier A, Leduc H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 2013; 61 : 948–54. [CrossRef] [PubMed] [Google Scholar]
- Buyse GM, Voit T, Schara U, et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet 2015; 385 : 1748–56. [CrossRef] [PubMed] [Google Scholar]
- McDonald CM, Meier T, Voit T, et al. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. Neuromuscul Disord 2016; 26 : 473–80. [PubMed] [Google Scholar]
- Leheup B, Himon F, Morali A, et al. Intérêt de la mexilétine dans le traitement de la myotonie de Thomsen-Becker. Arch Fr Pediatr 1986; 43 : 49–50. [EDP Sciences] [Google Scholar]
- Logigian EI, Martens WB, Moxley IV RT, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010; 74 : 1441–8. [CrossRef] [PubMed] [Google Scholar]
- Gordon KE, Dooley JM, Sheppard KM, et al. Impact of biphosphonates on survival for patients with Duchenne muscular dystrophy. Pediatrics 2011; 127 : e353–8. [PubMed] [Google Scholar]
- Wagner S, Poirot I, Vuillerot C, Berard C. Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders. Ann Phys Rehab Med 2011; 54 : 348–58. [CrossRef] [Google Scholar]
- Eymard B, Stojkovic T, Sternberg D, et al. Syndromes myasthéniques congénitaux : difficultés diagnostiques, évolution et pronostic, thérapeutique. L’expérience du réseau national Syndromes myasthéniques congénitaux. Rev Neurol 2013; 169 : S45–5. [Google Scholar]
- Pane M, Lombardo ME, Alfieri P, D’Amico A, et al. Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy : phenotype-genotype correlation. J Pediatr 2012; 161 : 705–9. [CrossRef] [PubMed] [Google Scholar]
- Douniol M, Jacquette A, Cohen D, et al. Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1. Dev Med Child Neurol 2012; 54 : 905–11. [CrossRef] [PubMed] [Google Scholar]
- Ishigaki K, Muto A, Osawa M. Clinical features and care of patients with congenital and childhood onset myotonic dystrophy. Rinsho Shinkeigaku 2012; 52 : 1264–6. [CrossRef] [PubMed] [Google Scholar]
- Merlini L, Sabatelli P. Improving clinical trial design for Duchenne muscular dystrophy. BMC Neurol 2015; 15 : 153. [CrossRef] [PubMed] [Google Scholar]
- Wirth B, Barkats M, Martinat C, et al. Moving towards treatments for spinal muscular atrophy: hopes and limits. Expert Opin Emerging Drugs 2015; 20 : 352–6. [CrossRef] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.